Monopar, National University of Singapore Team Up For Preclinical Assessment Of MNPR-202 In Cancer Settings

Monopar Therapeutics Inc MNPR collaborates with the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in multiple types of cancer.
MNPR-202 was designed to retain the same potentially non-cardiotoxic backbone as camsirubicin but is modified, which may enable it to work in certain cancers that are resistant to camsirubicin and doxorubicin (chemo).
The company expects camsirubicin to enter a dose-escalation run-in clinical trial in advanced soft tissue sarcoma in the second half of 2021.
CSI Singapore will explore how the immune system recognizes cancer cells treated with MNPR-202 and related analogs.
Price Action: MNPR shares are down 0.65% at $6.09 during the market session on the last check Thursday.